0001157523-23-000830.txt : 20230512 0001157523-23-000830.hdr.sgml : 20230512 20230512160121 ACCESSION NUMBER: 0001157523-23-000830 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230512 FILED AS OF DATE: 20230512 DATE AS OF CHANGE: 20230512 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Legend Biotech Corp CENTRAL INDEX KEY: 0001801198 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: E9 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39307 FILM NUMBER: 23915423 BUSINESS ADDRESS: STREET 1: 2101 COTTONTAIL LANE CITY: SOMERSET STATE: NJ ZIP: 08873 BUSINESS PHONE: 732-317-5050 MAIL ADDRESS: STREET 1: 2101 COTTONTAIL LANE CITY: SOMERSET STATE: NJ ZIP: 08873 6-K 1 a53399497.htm LEGEND BIOTECH CORPORATION 6-K



 
 
UNITED STATES
 SECURITIES AND EXCHANGE COMMISSION
 Washington, D.C. 20549
 
 
 
  FORM 6-K
 
 
 
 
 Report of Foreign Private Issuer
 Pursuant to Rule 13a-16 or 15d-16
 of the Securities Exchange Act of 1934
 
 Date of Report: May 12, 2023
 
  Commission File Number: 001-39307
 
 
 
  Legend Biotech Corporation
 (Exact Name of Registrant as Specified in its Charter)
 
 
 

 2101 Cottontail Lane
 Somerset, New Jersey 08873
 (Address of principal executive office)
 
 
 

 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
 
Form 20-F ☒            Form 40-F  ☐
  
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ☐
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ☐
 
 
1
Legend Biotech Corporation Reports Exercise of Warrant
 
 On May 12, 2023, Legend Biotech Corporation (the “Company”) announced that LGN Holdings Limited (the “Warrant Holder”) exercised in full its warrant (the “Warrant”) to purchase 10,000,000 ordinary shares, par value US$0.0001 per share of the Company, at an exercise price of US$20.00 per Ordinary Share for an aggregate exercise price of US$200,000,000, and, as a result, the Company issued the 10,000,000 Ordinary Shares to the Warrant Holder.
2
SIGNATURES

 Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 

 
 
LEGEND BIOTECH CORPORATION
 
 
 
Date: May 12, 2023
By:
/s/ Lori Macomber
 
Name:
Lori Macomber
 
Title:
Chief Financial Officer

3